구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Tralokinumab |
Overview Company | LEO Pharma |
Overview Modality | ANTIBODY |
Overview Target | Atopic Dermatitis |
Overview Indication | Psoriasis; Atopic Dermatitis |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
Positioning Key differentiator | Novel systemic treatments can not only provide effective relief for these patients but can also be cost saving |
MoA Mechanism | is still under investigation (5,6) |
MoA Biomarker | biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses |
PK/PD Animal (cat.) | Human |
PK/PD Experiment | pd |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | Effectiveness, biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses stratified by age groups (15-17, 18-64, and ≥ 65 years).. Tralokinumab, an anti-interleukin-13 monoclonal antibody, is effective for atopic dermatitis (AD). However, long-term (one-year) clinical outcomes stratified by age groups have not been sufficiently studied. To… |
Clinical Safety signal | Effectiveness, biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses stratified by age groups (15-17, 18-64, and ≥ 65 years).. Tralokinumab, an anti-interleukin-13 monoclonal antibody, is effective for atopic dermatitis (AD). However, long-term (one-year) clinical outcomes stratified by age groups have not been sufficiently studied. To… |
Clinical Selected reported efficacy | 100% |
Clinical Result source | ClinicalTrials.gov NCT02684097 |
Clinical Program phase | APPROVED |
Clinical Trial ref | NCT02684097 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Tralokinumab |
Overview Company | LEO Pharma |
Overview Modality | ANTIBODY |
Overview Target | Atopic Dermatitis |
Overview Indication | Psoriasis; Atopic Dermatitis |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
Positioning Key differentiator | Novel systemic treatments can not only provide effective relief for these patients but can also be cost saving |
MoA Mechanism | is still under investigation (5,6) |
MoA Biomarker | biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses |
PK/PD Animal (cat.) | Human |
PK/PD Experiment | pd |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | Effectiveness, biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses stratified by age groups (15-17, 18-64, and ≥ 65 years).. Tralokinumab, an anti-interleukin-13 monoclonal antibody, is effective for atopic dermatitis (AD). However, long-term (one-year) clinical outcomes stratified by age groups have not been sufficiently studied. To… |
Clinical Safety signal | Effectiveness, biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses stratified by age groups (15-17, 18-64, and ≥ 65 years).. Tralokinumab, an anti-interleukin-13 monoclonal antibody, is effective for atopic dermatitis (AD). However, long-term (one-year) clinical outcomes stratified by age groups have not been sufficiently studied. To… |
Clinical Selected reported efficacy | 100% |
Clinical Result source | ClinicalTrials.gov NCT02684097 |
Clinical Program phase | APPROVED |
Clinical Trial ref | NCT02684097 |
추천 비교
추천 비교